• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effectiveness of guselkumab for avelumab-induced psoriasis in urothelial carcinoma: A case report.

作者信息

Yatsuzuka Kazuki, Yoshida Satoshi, Miura Noriyoshi, Kohri Nobushige, Muto Jun, Shiraishi Ken, Fujisawa Yasuhiro

机构信息

Department of Dermatology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.

Department of Urology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.

出版信息

J Dermatol. 2025 Feb;52(2):e147-e148. doi: 10.1111/1346-8138.17583. Epub 2024 Dec 12.

DOI:10.1111/1346-8138.17583
PMID:39663870
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11807355/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afd9/11807355/d0717837d50f/JDE-52-e147-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afd9/11807355/d0717837d50f/JDE-52-e147-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afd9/11807355/d0717837d50f/JDE-52-e147-g001.jpg

相似文献

1
Effectiveness of guselkumab for avelumab-induced psoriasis in urothelial carcinoma: A case report.古塞库单抗治疗阿维鲁单抗诱导的尿路上皮癌银屑病的疗效：一例报告。
J Dermatol. 2025 Feb;52(2):e147-e148. doi: 10.1111/1346-8138.17583. Epub 2024 Dec 12.
2
Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland.苏格兰晚期尿路上皮癌avelumab 一线维持治疗的成本效果分析。
Future Oncol. 2024 Mar;20(8):459-470. doi: 10.2217/fon-2023-0372. Epub 2023 Aug 2.
3
Cost-Effectiveness of Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma in the United States.阿维鲁单抗维持治疗用于美国晚期或转移性尿路上皮癌的成本效果分析。
Adv Ther. 2021 Dec;38(12):5710-5720. doi: 10.1007/s12325-021-01950-0. Epub 2021 Oct 24.
4
A cost-effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan.台湾地区局部晚期或转移性尿路上皮癌患者一线维持治疗中avelumab 联合最佳支持治疗对比最佳支持治疗单独应用的成本效果分析。
Cancer Rep (Hoboken). 2023 Oct;6(10):e1887. doi: 10.1002/cnr2.1887. Epub 2023 Aug 28.
5
Management and desensitization to Avelumab in anaphylaxis and metastatic urothelial carcinoma: A case report.阿维鲁单抗用于过敏反应和转移性尿路上皮癌的管理与脱敏：一例报告
J Oncol Pharm Pract. 2025 Jul;31(5):839-841. doi: 10.1177/10781552241313057. Epub 2025 Feb 13.
6
J-AVENUE: A retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan.J-AVENUE：一项回顾性真实世界研究，评估在日本接受阿维鲁单抗一线维持治疗的晚期尿路上皮癌患者的特征和结局。
Int J Urol. 2024 Aug;31(8):859-867. doi: 10.1111/iju.15473. Epub 2024 May 9.
7
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.阿维鲁单抗治疗铂类治疗失败后的转移性尿路上皮癌（JAVELIN Solid Tumor）：一项开放标签、1 期试验两个扩展队列的汇总结果。
Lancet Oncol. 2018 Jan;19(1):51-64. doi: 10.1016/S1470-2045(17)30900-2. Epub 2017 Dec 5.
8
First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study.一线阿维鲁单抗联合化疗治疗晚期实体瘤患者：来自 Ib/II 期 JAVELIN 化疗联合研究的结果。
Cancer Res Commun. 2024 Jun 28;4(6):1609-1619. doi: 10.1158/2767-9764.CRC-23-0459.
9
Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: a cohort study.在中重度银屑病患者中，根据基础特征使用古塞库单抗的疗效、生存和安全性：一项队列研究。
F1000Res. 2022 Oct 17;11:1178. doi: 10.12688/f1000research.122945.2. eCollection 2022.
10
The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma.JAVELIN Bladder Medley 试验：avelumab 为基础的联合方案作为晚期尿路上皮癌的一线维持治疗。
Future Oncol. 2024 Feb;20(4):179-190. doi: 10.2217/fon-2023-0492. Epub 2023 Sep 6.

引用本文的文献

1
JAK Inhibitors and Inflammatory Nail Disorders: A Systematic Review of Clinical Outcomes and Therapeutic Potential.JAK抑制剂与炎症性甲病：临床结局与治疗潜力的系统评价
Am J Clin Dermatol. 2025 Apr 23. doi: 10.1007/s40257-025-00946-8.

本文引用的文献

1
Biological Agents for Treating Atezolizumab-Induced Psoriasis in Small-Cell Lung Cancer: A Case Report.治疗小细胞肺癌中阿替利珠单抗诱导的银屑病的生物制剂：一例报告
Cureus. 2024 May 30;16(5):e61395. doi: 10.7759/cureus.61395. eCollection 2024 May.
2
Immune Checkpoint Inhibitor-Induced Psoriasis: Diagnosis, Management, and a Review of Cases.免疫检查点抑制剂相关银屑病：诊断、治疗及病例复习
Dermatol Clin. 2024 Jul;42(3):481-493. doi: 10.1016/j.det.2024.02.012. Epub 2024 Mar 15.
3
The use of interleukin-23 inhibitors to treat immune-related psoriasis induced by immune checkpoint inhibitors and in patients with active cancer: A case series and review of the literature.
白细胞介素-23抑制剂用于治疗免疫检查点抑制剂诱导的免疫相关性银屑病及活动性癌症患者：病例系列及文献综述
SAGE Open Med Case Rep. 2023 Jun 16;11:2050313X231181035. doi: 10.1177/2050313X231181035. eCollection 2023.
4
Biologic treatment of psoriasis in oncologic patients.肿瘤患者银屑病的生物治疗。
Expert Opin Biol Ther. 2022 Dec;22(12):1567-1578. doi: 10.1080/14712598.2022.2152322.
5
Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group.免疫检查点介导的银屑病：来自欧洲皮肤不良反应与肿瘤药物网络（ENCADO）组的 115 例患者的多中心欧洲研究。
J Am Acad Dermatol. 2021 May;84(5):1310-1320. doi: 10.1016/j.jaad.2020.08.137. Epub 2020 Dec 3.